Navigation Links
Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Date:11/11/2008

BASKING RIDGE, N.J. and DURHAM, N.C., Nov. 11 /PRNewswire/ -- Regado Biosciences, Inc., today announced the appointment of Alexander R. Giaquinto, Ph.D., to the newly created position of Senior Vice President of Regulatory Affairs and Quality Assurance, effective immediately. Dr. Giaquinto brings to Regado over 35 years of experience in the pharmaceutical industry, including 30 years at Schering-Plough where he held executive management positions in the areas of Worldwide Regulatory Affairs and Compliance.

In his new position, Dr. Giaquinto will report to Dr. David J. Mazzo, Ph.D., Regado's President and Chief Executive Officer, and will be based in the Company's recently established office in Basking Ridge, New Jersey. The Company's locations in both Basking Ridge and Durham, North Carolina will have members of the executive management team and development staff.

Dr. Mazzo stated, "We are tremendously pleased to welcome someone of Dr. Giaquinto's vast experience to Regado's management team. His long-standing regulatory expertise will be essential as the Company further advances its lead therapeutic candidate, the REG1 Anticoagulation System, into late-stage clinical development." Regado recently announced completion of enrollment in the Company's Phase IIa clinical study (REVERSAL-PCI) in patients undergoing elective percutaneous coronary intervention.

Dr. Giaquinto attained the level of Senior Vice President, Worldwide Regulatory Affairs, as well as being named to a special post reporting directly to the CEO overseeing Global Compliance at Schering-Plough. These experiences, coupled with that gained as the U.S. Industry Representative of the Steering Committee of the International Conference on Harmonization (ICH), has allowed him to acquire a unique understanding of national and international regulatory processes, including regulatory submissions, reviews and approvals. At Schering-Plough, Dr. Giaquinto was instrumental in establishing the development and regulatory strategies for the approvals of 74 New Drug Applications (NDAs) and Supplements, nine Biologic License Applications (BLAs) and 28 Abbreviated NDAs.

Dr. Giaquinto currently is a Director of SemBioSys Genetics, Biothera, and PQRI. He is also a member of the Advisory Boards of Avaan Therapeutics, Allozyne Inc., Sagamore Capital and EndoCeutics, and served on, as well as chaired, the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Dr. Giaquinto participates in a number of charitable activities, including as Director on the Board of Trustees of the Children's Specialized Hospital and Chairman of the Board for Children's Specialized Hospital Foundation, both in Mountainside, NJ, and Chairman of the Board of Caldwell College in New Jersey. Dr. Giaquinto earned a Bachelor of Science in Pharmacy from St. John's University and a Ph.D. in Pharmaceutics from the University of Connecticut.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alexander M. Cutler Nominated for Election to DuPont Board of Directors
2. New Alexander, the Elephant Who Couldnt Eat Peanuts DVDs Help Children With Food Allergies
3. Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
6. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
7. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
8. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
9. Trust for Americas Health Joins GAO in Calling for Next Administration to Focus on Urgent Public Health Issues as Top Priorities
10. Diabetes Dad Tom Karlya Rejoins Diabetes Research Institute Foundation
11. Groseth Rejoins EMSI to Lead Healthcare Services Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... , ... Doctors on Liens is continuing its steady expansion of medical specialties ... at North Valley Eye Medical Group in Mission Hills . Eye injuries and ... injury cases. These injuries have a major impact on the quality of life ...
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... throughout the country today, as organizations, advocates, and individuals join together to increase ... treatment access to ultimately save lives. , “Today we mark a nationwide movement ...
(Date:2/22/2017)... ... 2017 , ... The Centers for Medicare & Medicaid Services ... Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in the ... of 2015 (MACRA). , This technical assistance, authorized and funded under MACRA, ...
(Date:2/22/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... of Platelet Rich Plasma (PRP). PRP systems are used by physicians in areas ... and provide a faster and more efficient healing process. There are many systems ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Mixed tocopherols market projected to grow at ... is projected to reach USD 5.27 billion by 2022, at ... by factors such as health and wellness trends, for instance, ... regulations for sourcing, processing, packaging, and labeling of food & ... such as the Asia-Pacific region also ...
(Date:2/22/2017)... a condition where an organ of ... to weak abdominal wall. Hernia is classified into ... femoral hernia, umbilical hernia, and other (hiatal hernia ... are performed using a mesh, made-up of biological ... Among the available options, open tension-free repair procedures ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605680-summary/view-report.html Description The Global Spinal Cord Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
Breaking Medicine Technology: